Furthermore, if subpopulations of spinal cord microglia or astrocytes of AMN patients were lacking physiological neuroprotective functions, ABCD1-based gene therapy targeting these cell types would be beneficial. Here, ABCD1 is linked to adrenomyeloneuropathy.